After a series of acquisitions and an activist investor’s accusation of overspending, Pfizer is exploring an opportunity to ...
Pfizer's head of digital devices says the industry is close to a 'revolution' in using measures from wearables in clinical ...
Centessa had recently conducted an interim analysis of a phase 2 study of its drug, called SerpinPC, which is designed to ...
Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant.
One company value investors might notice is Pfizer (PFE). PFE is currently holding a Zacks Rank of #2 (Buy) and a Value grade of A. The stock is trading with a P/E ratio of 9.16, which compares to ...
On Friday, Pfizer Inc (PFE) stock saw a decline, ending the day at $26.72 which represents a decrease of $-0.74 or -2.69% from the prior close of $27.46. The stock opened at $27.11 and touched a low ...
Pfizer's stock underperforms the S&P 500, facing patent expirations and competition, yet offers a 6.3% forward dividend yield. Despite a positive Q3 earnings surprise, profitability remains weaker ...
Pfizer Limited is expanding its manufacturing capacity and focusing on research and development, said Meenakshi Nevatia, ...
Pfizer India Country President Meenakshi Nevatia reiterated the multinational’s commitment to India highlighting its ‘Make In ...